Research Article| Volume 68, ISSUE 4, P672-681, April 2018

Download started.


96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

Published:January 16, 2018DOI:


      • TAF is a new prodrug of tenofovir developed to treat patients with chronic HBV.
      • A lower dose of TAF can be used because it delivers tenofovir more efficiently to hepatocytes than TDF.
      • At week 48, TAF had non-inferior efficacy to TDF with improved renal and bone safety.
      • Efficacy and safety results at week 96 confirm the 48-week results in both studies.

      Background & Aims

      Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir disoproxil fumarate (TDF) through more efficient delivery of tenofovir to hepatocytes. In 48-week results from two ongoing, double-blind, randomized phase III trials, TAF was non-inferior to TDF in efficacy with improved renal and bone safety. We report 96-week outcomes for both trials.


      In two international trials, patients with chronic HBV infection were randomized 2:1 to receive 25 mg TAF or 300 mg TDF in a double-blinded fashion. One study enrolled HBeAg-positive patients and the other HBeAg-negative patients. We assessed efficacy in each study, and safety in the pooled population.


      At week 96, the differences in the rates of viral suppression were similar in HBeAg-positive patients receiving TAF and TDF (73% vs. 75%, respectively, adjusted difference −2.2% (95% CI −8.3 to 3.9%; p = 0.47), and in HBeAg-negative patients receiving TAF and TDF (90% vs. 91%, respectively, adjusted difference −0.6% (95% CI −7.0 to 5.8%; p = 0.84). In both studies the proportions of patients with alanine aminotransferase above the upper limit of normal at baseline, who had normal alanine aminotransferase at week 96 of treatment, were significantly higher in patients receiving TAF than in those receiving TDF. In the pooled safety population, patients receiving TAF had significantly smaller decreases in bone mineral density than those receiving TDF in the hip (mean % change −0.33% vs. −2.51%; p <0.001) and lumbar spine (mean % change −0.75% vs. −2.57%; p <0.001), as well as a significantly smaller median change in estimated glomerular filtration rate by Cockcroft-Gault method (−1.2 vs. −4.8 mg/dl; p <0.001).


      In patients with HBV infection, TAF remained as effective as TDF, with continued improved renal and bone safety, two years after the initiation of treatment. number: NCT01940471 and NCT01940341.

      Lay summary

      At week 96 of two ongoing studies comparing the efficacy and safety of tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) for the treatment of chronic hepatitis B patients, TAF continues to be as effective as TDF with continued improved renal and bone safety.
      Registration: number: NCT01940471 and NCT01940341.

      Graphical abstract


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. World Health Organization. Hepatitis B fact sheet.

        • Ganem D.
        • Prince A.M.
        Hepatitis B virus infection—natural history and clinical consequences.
        N Engl J Med. 2004; 350: 1118-1129
        • McMahon B.J.
        Chronic hepatitis B virus infection.
        Med Clin North Am. 2014; 98: 39-54
        • Fattovich G.
        • Bortolotti F.
        • Donato F.
        Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.
        J Hepatol. 2008; 48: 335-352
        • Gish R.G.
        • Given B.D.
        • Lai C.-L.
        • Locarnini S.A.
        • Lau J.Y.
        • Lewis D.L.
        • et al.
        Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities.
        Antivir Res. 2015; 121: 47-58
        • Marcellin P.
        • Gane E.
        • Buti M.
        • Afdahl N.
        • Sievert W.
        • Jacobson I.M.
        • et al.
        Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
        Lancet. 2013; 381: 468-475
        • Peng C.Y.
        • Chien R.N.
        • Liaw Y.F.
        Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy.
        J Hepatol. 2012; 57: 442-450
        • Terrault N.A.
        • Bzowej N.H.
        • Chang K.-M.
        • Hwang J.P.
        • Jonas M.M.
        • Murad M.H.
        AASLD guidelines for treatment of chronic hepatitis B.
        Hepatology. 2016; 63: 261-283
        • European Association for the Study of the Liver
        EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection.
        J Hepatol. 2017; 67: 370-398
        • Gill U.S.
        • Zissimopoulos A.
        • Al-Shamma S.
        • Burke K.
        • McPhail M.J.
        • Barr D.A.
        • et al.
        Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: Can the fracture risk assessment tool identify those at greatest risk?.
        J Infect Dis. 2015; 211: 374-382
        • Chen C.H.
        • Lin C.L.
        • Kao C.H.
        Association between chronic hepatitis B virus infection and risk of osteoporosis: a nationwide population-based study.
        Medicine. 2015; 94: e2276
        • Chen Y.C.
        • Su Y.C.
        • Li C.Y.
        • Hung S.K.
        13-year nationwide cohort study of chronic kidney disease risk among treatmen-naïve patients with chronic hepatitis B in Taiwan.
        BMC Nephrology. 2015; 16: 110
        • Maggi P.
        • Montinaro V.
        • Leone A.
        • Fasano M.
        • Volpe A.
        • Bellacosa C.
        • et al.
        Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study.
        J Antimicrob Chemother. 2015; 70: 1150-1154
        • Lee W.A.
        • He G.X.
        • Eisenberg E.
        • Cihlar T.
        • Swaminathan S.
        • Mulato A.
        • et al.
        Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.
        Antimicrob Agents Chemother. 2005; 49: 1898-1906
        • De Clercq E.
        Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
        Biochem Pharmacol. 2016; 119: 1-7
        • Delaney 4th, W.E.
        • Ray A.S.
        • Yang H.
        • Qi X.
        • Xiong S.
        • Zhu Y.
        • et al.
        Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.
        Antimicrob Agents Chemother. 2006; 50: 2471-2477
        • Babusis D.
        • Phan T.K.
        • Lee W.A.
        • Watkins W.J.
        • Ray A.S.
        • et al.
        Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340.
        Mol Pharmaceutics. 2013; 10: 459-466
        • Murakami E.
        • Wang T.
        • Park Y.
        • Hao J.
        • Lepist E.l.
        • Babusis D.
        • et al.
        Implications of efficient hepatic delivery by TAF (GS-7340) for hepatitis B virus therapy.
        Antimicrob Agents Chemother. 2015; 59: 3563-3569
        • Hall A.M.
        • Hendry B.M.
        • Nitsch D.
        • Connolly J.O.
        Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
        Am J Kidney Dis. 2011; 57: 773-780
        • Gara N.
        • Zhao X.
        • Collins M.T.
        • Chong W.H.
        • Kleiner D.E.
        • Liang T.J.
        • et al.
        Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.
        Aliment Pharmacol Ther. 2012; 35: 1317-1325
        • Brown T.T.
        • Moser C.
        • Currier J.S.
        • Ribaudo H.J.
        • Rothenberg J.
        • Kelesidis T.
        • et al.
        Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir.
        J Infect Dis. 2015; 212: 1241-1249
        • Agarwal K.
        • Fung S.K.
        • Nguyen T.T.
        • Cheng W.
        • Sicard E.
        • Ryder S.D.
        • et al.
        Twenty-eight day safety, antiviral activity, and pharmacokinetics of TAF for treatment of chronic hepatitis B infection.
        J Hepatol. 2015; 62: 533
        • Ruane P.J.
        • DeJesus E.
        • Berger D.
        • Markowitz M.
        • Bredeek U.F.
        • Callebaut C.
        • et al.
        Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of TAF as 10-day monotherapy in HIV-1-positive adults.
        J Acquir Immune Defic. 2013; 63: 449-455
        • Buti M.
        • Gane E.
        • Seto W.K.
        • Chan H.L.
        • Chuang W.L.
        • Stepanova T.
        • et al.
        TAF vs. tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet.
        Gastroenterol Hepatol. 2016; 1: 196-206
        • Chan H.L.
        • Fung S.
        • Seto W.K.
        • Chuang W.L.
        • Chen C.Y.
        • Kim H.J.
        • et al.
        TAF vs. tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet.
        Gastroenterol Hepatol. 2016; 1: 185-195
        • Santos J.R.
        • Saumoy M.
        • Curran A.
        • Bravo I.
        • Libre J.M.
        • Navarro J.
        • et al.
        The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.
        Clin Infect Disease. 2015; 61: 403-408
        • Tungsiripat M.
        • Kitch D.
        • Glesby M.J.
        • Gupta S.K.
        • Mellors J.W.
        • Moran L.
        • et al.
        A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
        AIDS. 2010; 24: 1781-1784
        • Fung S.
        • Kwan P.
        • Fabri M.
        • Horban A.
        • Pelemis M.
        • Hann H.W.
        • et al.
        Randomized comparison of tenofovir disoproxil fumarate vs. emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
        Gastroenterology. 2014; 146: 980-988
        • Berg T.
        • Zoulim F.
        • Moeller B.
        • Trinh H.
        • Marcellin P.
        • Chan S.
        • et al.
        Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.
        J Hepatol. 2014; 60: 715-722
        • Cosman F.
        • de Beur S.J.
        • LeBoff M.S.
        • Lewiecki E.M.
        • Tanner B.
        • Randall S.
        • et al.
        Erratum to: Clinician’s guide to prevention and treatment of osteoporosis.
        Osteoporos Int. 2015; 26: 2045-2047
        • Viganò M.
        • Brocchieri A.
        • Spinetti A.
        • Zaltron S.
        • Mangia G.
        • Facchetti F.
        • et al.
        Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal.
        J Clin Virol. 2014; 61: 600-603
        • Gracey D.M.
        • Snelling P.
        • McKenzie P.
        • Strasser S.I.
        Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection.
        Antivir Ther. 2013; 18: 945-948
        • Sarin S.K.
        • Kumar M.
        • Lau G.K.
        • Abbas Z.
        • Chan H.L.
        • Chen C.J.
        • et al.
        Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
        Hepatol Int. 2016; 10: 1-98
        • Chan H.L.
        • Fung S.
        • Seto W.K.
        • Gane E.
        • Flaherty J.F.
        • Suri V.
        • et al.
        Improved bone and renal safety of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF): results from 2 Phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B.
        J Hepatol. 2017; 66 (abstract PS-041): S25